Randy Calegari, MD
Hematology & Oncology · Las Vegas, NVNPI 1336263953
Payments from drug & device makers
Across 156 payments — averaging $16.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Exelixis Inc.$223
- Novartis$182
- Johnson & Johnson$177
- Astellas Pharma US Inc$176
- Amgen$174
- AbbVie$171
- plus $1K from 32 others
What the payments were for
- Food & beverage$2,50798%
- Education$432%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Exelixis Inc. | 12 | $223 |
| Novartis | 13 | $182 |
| Johnson & Johnson(2 entities) | 12 | $177 |
| Astellas Pharma US Inc | 13 | $176 |
| Amgen | 11 | $174 |
| AbbVie | 4 | $171 |
| AstraZeneca(2 entities) | 12 | $146 |
| Merck | 10 | $141 |
| Pfizer | 12 | $119 |
| Regeneron Healthcare Solutions, Inc. | 1 | $104 |
| EMD Serono, Inc. | 5 | $71 |
| Bayer | 4 | $67 |
| Pharmacyclics LLC, An Abbvie Company | 3 | $56 |
| Eisai Inc. | 3 | $53 |
| Foundation Medicine, Inc. | 2 | $51 |
| E.r. Squibb & Sons, L.L.C. | 3 | $46 |
| Daiichi Sankyo Inc. | 3 | $46 |
| Puma Biotechnology, Inc. | 3 | $46 |
| Seagen Inc. | 2 | $42 |
| Octapharma USA, Inc. | 2 | $36 |
| Tesaro, Inc. | 2 | $36 |
| Bristol Myers Squibb | 2 | $35 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $33 |
| Clovis Oncology, Inc. | 4 | $33 |
| Incyte Corporation | 2 | $30 |
| Sanofi | 2 | $30 |
| Boehringer Ingelheim | 1 | $25 |
| Karyopharm Therapeutics Inc. | 1 | $24 |
| AMAG Pharmaceuticals, Inc. | 1 | $24 |
| Taiho Oncology, Inc. | 1 | $21 |
| Dova Pharmaceuticals | 1 | $20 |
| GSK | 1 | $19 |
| Janssen Scientific Affairs, LLC | 1 | $17 |
| Agios Pharmaceuticals, Inc. | 1 | $17 |
| Heron Therapeutics, Inc. | 1 | $17 |
| Verastem, Inc. | 1 | $15 |
| Genentech USA, Inc. | 1 | $14 |
| Dendreon Pharmaceuticals LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,550 in reported general payments places this provider in the 15th percentile of 82 hematology & oncology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 43 | $781,615 |
| EmpaveliPegcetacoplan | 14 | $556,982 |
| CalquenceAcalabrutinib Maleate | 33 | $498,514 |
| XtandiEnzalutamide | 29 | $404,975 |
| VenclextaVenetoclax | 28 | $311,503 |
| NubeqaDarolutamide | 18 | $240,910 |
| VerzenioAbemaciclib | 14 | $196,693 |
| ErleadaApalutamide | 12 | $168,215 |
| Lenalidomide | 11 | $163,971 |
| BrukinsaZanubrutinib | 11 | $159,158 |
| Abiraterone Acetate | 56 | $83,106 |
| EliquisApixaban | 34 | $22,584 |
| Imatinib Mesylate | 25 | $7,685 |
| Megestrol Acetate | 45 | $2,343 |
| Hydroxyurea | 60 | $1,174 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $35 | $781,61543 claims |
| AstraZenecaCalquence | $146 | $498,51433 claims |
| Astellas Pharma US IncXtandi | $176 | $404,97529 claims |
| AbbVieVenclexta | $171 | $311,50328 claims |
| BayerNubeqa | $67 | $240,91018 claims |
| Johnson & JohnsonErleada | $177 | $168,21512 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $17 | $83,10656 claims |
| PfizerEliquis | $119 | $22,58434 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 82 hematology & oncology providers in Nevada.
Other hematology & oncology in Las Vegas
- Edwin KingsleyLas Vegas$9.2M
- Nicholas VogelzangLas Vegas$8.3M
- Oscar GoodmanLas Vegas$6M
- Khawaja JahangirLas Vegas$2.5M
- Carolyn MulroneyLas Vegas$1.5M
- Wolfram SamlowskiLas Vegas$1.1M
- Anuradha ThummalaLas Vegas$736K
- Grzegorz ObaraLas Vegas$668K
- Aaron GoodmanLas Vegas$480K
- Vikas GuptaLas Vegas$300K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.